Association of Circulating Platelet Extracellular Vesicles and Pulse Wave Velocity with Cardiovascular Risk Estimation
19 Pages Posted: 1 Apr 2022
Background: Elevated circulating platelet-derived extracellular vesicles (EV) have been reported in conditions associated with thrombotic risk. The present study aimed to assess the relationship between circulating platelet-derived EV levels, cardiovascular risk stratification and vascular organ damage as assessed by pulse wave velocity (PWV).
Methods: A total of 92 patients were included in the present analysis. Platelet EV were evaluated by flow cytometry (CD41+/Annexin v+). The cardiovascular risk was determined using the 2021 ESC guideline stratification and SCORE2 and SCORE-OP. PWV was performed as a surrogate to assess macrovascular damage.
Results: Risk stratification revealed significant group differences in EV levels (ANOVA, p=0.04). Posthoc analysis demonstrated significant higher levels of EV in the very high-risk group compared with the young participants (12.53±8.69 vs 7.51±4.67 EV/µL, p=0.03). Linear regression models showed SCORE2 and SCORE-OP (p=0.04) was a predictor of EV levels. EVs showed a significant association with macrovascular organ damage measured by PWV (p=0.01). PWV progressively increased with more severe cardiovascular risk (p<0.001) and was also associated with SCORE2 and SCORE-OP (p<0.001). Within the pooled group of subjects with low to moderate risk and young participants (<40 years), those with EV levels in the highest tertile had a trend towards higher nocturnal blood pressure levels, fasting glucose concentration, lipid levels, homocysteine and PWV.
Conclusion: Levels of platelet derived EVs were highest in those patients with very high CV risk. Within a pooled group of patients with low to moderate risk, an unfavourable cardiometabolic profile was present with higher EV levels.
Funding Information: This research received no grant from any funding agency.
Declaration of Interests: MPS is supported by an NHMRC Research Fellowship and has received consulting fees, and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer-Ingelheim; LMLG has received a grant from the National Council on Science and Technology, Mexico (CONACYT). All other authors have no conflict of interest to declare.
Ethics Approval Statement: The study complied with the Declaration of Helsinki and received approval from the University of Western Australia research ethics committee. All participants provided written consent for the study.
Keywords: thrombosis, Platelets, Extracellular vesicles, cardiovascular risk
Suggested Citation: Suggested Citation